CA
NZ
UK
AU
IND
US
MYQORZO (aficamten) was approved by the FDA in December 2025 and became available to patients around January 27, 2026. The European Commission approved it in February 2026, the United Kingdom granted aMarketingauthorization in July, and Health Canada issued a Notice of Compliance in October. …
The company attributed the growth in service fees to an approximate 18% increase in average monthly transacting Members, ExtraCash originations of approximately USD 2.5 billion against approximately USD 2.0 billion, and an average ExtraCash amount of USD 218 against USD 207. It also cited …
The company said it does not see significant additional restructuring charges in 2026 from the 2025 Restructuring Plan, which it adopted in response to macroeconomic pressures. It also completed two divestitures from the Industrial Solutions segment: Geomagic, sold on April 1, 2025 for USD …
Total revenue was USD 108.5 million against USD 499.8 million in the third quarter of 2025. Derivatives produced a loss of USD 378.4 million against a gain of USD 111.0 million a year earlier. Commodity revenue was USD 469.6 million against USD 372.8 million.
ClearanceJobs revenue reached USD 16.507 million, against USD 13.937 million a year earlier, an increase of 18%. The company attributed the gain to continuedDemandfor professionals with government security clearance, consistent product releases and theAcquisitionof Point Solutions Group. Dice revenue was USD 15.733 million, against …
The CEO said revenue across the combined Payments and Data businesses grew by over 21%. Merchant Services revenue was USD 135.1 million against USD 98.0 million a year earlier, B2B Payments was USD 77.3 million against USD 73.1 million, and Data Solutions was USD …
The company develops antibody therapies for blood disorders driven by mutant calreticulin, with three candidates: DMR-001, DMR-002 and DMR-003. It began the CLARITY-101 trial of DMR-001 in essential thrombocythemia and myelofibrosis patients after receiving health authority approval in Australia, and it has since received …
The lead candidate, claseprubart, is a subcutaneous antibody that selectively inhibits active C1s. In chronic inflammatory demyelinating polyneuropathy (CIDP), the company reported a 75% response rate in the interim analysis of the first 40 participants completing Part A of the Phase 3 CAPTIVATE trial, …
The company described the May 2026 four-week intravenous data as positive. At the 1 mpk dose (four patients), mean improvements from baseline were 6.4 points on the mFARS scale and 2.7 points on the upright stability score. Whole blood FXN mRNA rose 65% from …
Prescription gammaCore for primary headache and Quell Fibromyalgia are the two leading products, with Truvaga and TAC-STIM serving the general wellness and human performance markets. The company said the majority of 2026Revenuecontinues to come from prescription sales to the VA. Sales to the UK …
Please wait processing your request...